The European Society for Medical Oncology (ESMO) is a non-profit professional medical oncology society in Europe. ESMO offers post-graduate education and training in clinical cancer care and research, and produces evidence-based recommendations for basic standards of cancer care.
Some content from Wikipedia, licensed under CC BY-SA
Subscribe to rss feed
Overweight and obesity are contributing to rising death rates from bowel cancer among people aged 25–49 years in the European Union (EU) and the UK, although death rates from this type of cancer are decreasing overall across ...
Jan 28, 2024
0
20
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumor cells, with less need for chemotherapy, following results of multiple clinical trials reported ...
Oct 18, 2023
0
0
Results from highly anticipated phase 3 clinical trials in gynecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress ...
Oct 18, 2023
0
0
Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas. Results of the first study to take account of ...
Oct 17, 2023
0
0
Artificial intelligence (AI) has made a grand entrance into the public debate this year, but researchers have long been investigating its potential to transform cancer care and improve patient outcomes. Dedicated sessions ...
Oct 16, 2023
0
0
A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the U.K., according to new research published in the journal Annals of Oncology today (March ...
Mar 6, 2023
0
4
The European Society for Medical Oncology (ESMO) has developed a quality of life (QoL) checklist that is now integral to the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS)—a validated and reproducible tool to assess ...
Dec 20, 2022
0
4
More than 1.4 million men were diagnosed with prostate cancer in 2020 globally, but the molecular characteristics of the disease remain unexplored for the majority of patients around the world. In the final days of the Movember ...
Nov 28, 2022
0
2
Significant improvement in progression free survival and response rate combined with reduced symptoms and better quality of life are reported as outcomes of a new treatment approach for patients with desmoid tumors, which ...
Sep 12, 2022
0
4
A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported ...
Sep 11, 2022
0
24
